Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Dovitinib (TKI258)

First Posted Date: 2011-11-23

Last Posted Date: 2016-04-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT01478373

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Spain

Efficacy of LCQ908 on Cardiovascular Risk

Phase 2

Terminated

Conditions: Hypertriglyceridemia
Coronary Artery Disease

Interventions: Drug: pradigastat (LCQ908)
Drug: Placebo

First Posted Date: 2011-11-18

Last Posted Date: 2016-04-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 41

Registration Number: NCT01474434

Locations: 🇺🇸
Novartis Investigative Site, Pasadena, California, United States

Safety and Tolerability of HSC835 in Patients With Hematological Malignancies

Phase 1

Completed

Conditions: Chronic Lymphocytic Leukemia
Lymphoblastic Lymphoma
High Grade Lymphomas
Acute Myelocytic Leukemia
Burkitt's Lymphoma
Lymphoplasmacytic Lymphoma
Acute Lymphocytic Leukemia
Chronic Myelogenous Leukemia
Follicular Lymphomas
Myelodysplastic Syndrome

Interventions: Biological: HSC835

First Posted Date: 2011-11-18

Last Posted Date: 2020-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT01474681

Locations: 🇺🇸
Novartis Investigative Site, Minneapolis, Minnesota, United States

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Phase 2

Completed

Conditions: Dyskinesias
Drug-induced

Interventions: Drug: AQW051
Drug: Placebo

First Posted Date: 2011-11-18

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 71

Registration Number: NCT01474421

Locations: 🇮🇹
Novartis Investigative Site, Roma, RM, Italy

A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Phase 1

Completed

Conditions: Glioblastoma

Interventions: Drug: BKM120 +temozolomide with/without radiotherapy
Drug: BKM120 + temozolomide

First Posted Date: 2011-11-17

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 38

Registration Number: NCT01473901

Locations: 🇺🇸
Highlands Oncology Group Highlands Oncology, Fayetteville, Arkansas, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain
🇺🇸
Dana Farber Cancer Institute SC (1), Boston, Massachusetts, United States

and more 1 locations

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Phase 1

Completed

Conditions: Locally Advance Breast Cancer (LABC)
Metastatic Breast Cancer (MBC)

Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll)
Drug: Lapatinib + Capecitabine (Phase II)

First Posted Date: 2011-11-16

Last Posted Date: 2020-12-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT01471847

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Phase I Dose Escalating Study of TKI258

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: TKI258

First Posted Date: 2011-11-16

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT01471548

Locations: 🇯🇵
Novartis Investigative Site, Hidaka, Saitama, Japan

β-RELIEVED - REsponse in Acute fLare and In prEVEntion of episoDes of Re-flare in Gout - Extension 3 (E3)

Phase 3

Completed

Conditions: Acute Gouty Arthritis Flares

Interventions: Drug: ACZ885
Drug: Triamcinolone acetonide 40 mg

First Posted Date: 2011-11-11

Last Posted Date: 2021-07-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 136

Registration Number: NCT01470989

Locations: 🇺🇦
Novartis Investigative Site, Zaporizhzhya, Ukraine

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Phase 1

Completed

Conditions: 3rd Line GIST

Interventions: Drug: STI571
Drug: BKM120

First Posted Date: 2011-11-09

Last Posted Date: 2020-12-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT01468688

Locations: 🇺🇸
Seattle Cancer Care Alliance Onc, Seattle, Washington, United States
🇺🇸
Dana Farber Cancer Institute SC (2), Boston, Massachusetts, United States
🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Impact of Omalizumab on Corticosteroid Use, Emergency Room Visits and Hospitalizations

Withdrawn

Conditions: Asthma

First Posted Date: 2011-10-27

Last Posted Date: 2021-12-07

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT01460862

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy